[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628710":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":36,"interventions":48,"overallOfficials":25,"centralContacts":58,"locations":64,"responsibleParty":81,"collaborators":25,"id":85,"slug":25,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":25,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":25,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Benha University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"the duration of sensory block","time taken from intrathecal injection to sensory regression to S1 dermatome.","after anesthesia up to 12 hours postoperatively",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"the onset time of sensory block","time taken from intrathecal injection to the maternal feeling of lower extremities temperature increment or numbness","during 30 minutes after intrathecal injection",{"measure":19,"description":20,"timeFrame":17},"the onset time of motor block","time taken from intrathecal injection to MBS \\> 1",{"measure":22,"description":23,"timeFrame":24},"The recovery quality of parturients","ObsQoR-11, score from 0 to 10 in each term, where 0 = strongly agree and 10 = strongly disagree, the higher of the score, the higher of recovery quality","24 hours post-operatively",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":31,"maskingDescription":25,"whoMasked":32},"TRIPLE",[33,34,35],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[37,43],{"label":38,"type":39,"description":40,"interventionNames":41},"Group (B)","ACTIVE_COMPARATOR","will receive intra-thecal hyperbaric bupivacaine 11 mg(2.2 ml) of 0.5% bupivacaine, with 0.5 ml of normal saline in total volume 2.5 ml.",[42],"Drug: Bupivacaine",{"label":44,"type":39,"description":45,"interventionNames":46},"Group (BD)","will receive 9 mg (1.8 ml) of 0. 5% bupivacaine, with 5 μg of DEX in 0.5ml of normal saline in total volume 2.5 ml.",[47],"Drug: Bupivacaine and Dexmedetomidine",[49,54],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":25},"DRUG","Bupivacaine","patient will receive intra-thecal hyperbaric bupivacaine 11 mg(2.2 ml) of 0.5% bupivacaine, with 0.5 ml of normal saline in total volume 2.5 ml.",[38],{"type":50,"name":55,"description":56,"armGroupLabels":57,"otherNames":25},"Bupivacaine and Dexmedetomidine","patient will receive 9 mg (1.8 ml) of 0. 5% bupivacaine, with 5 μg of DEX in 0.5ml of normal saline in total volume 2.5 ml.",[44],[59],{"name":60,"role":61,"phone":62,"phoneExt":25,"email":63},"fatma ahmed abdelfatah, MD","CONTACT","00201091921540","drfatmaahmed86@gmail.com",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Banha Faculity of Medicine","RECRUITING","Banhā","Elqalyoubea,","13511","Egypt","EG",{"type":74,"coordinates":75},"Point",[76,77],31.1842,30.45977,{"lat":77,"lon":76},[80],{"name":60,"role":61,"phone":62,"phoneExt":25,"email":63},{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Fatma Ahmed Abdel Fatah","Assistant professor","100628710",false,"NCT07465185","Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery","Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery ;Arandomized Non - Inferiority Study","Inclusion Criteria:\n\n* (1) Full-term pregnant women undergoing elective cesarean section under spinal anesthesia. (2) Age: 20 \\~ 35 years. (3) ASA physical status II \\~ III\n\nExclusion Criteria:\n\n1. Multiple pregnancies.\n2. Cardiovascular disease(e.g., pre-eclampsia and hypertension).\n3. Serious hepatic dysfunction (Child-Pugh class C).\n4. serious renal dysfunction (undergoing dialysis before surgery).\n5. History of alcohol or opioid addiction.\n6. Contraindication to spinal anesthesia.\n7. Refusing to sign informed consent.","FEMALE","20 Years","35 Years",{"count":95,"type":96},300,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","Cesarean section (CS) is one of the most frequently performed surgical procedures globally, with an increasing demand for safe and effective anesthesia techniques. Regional anesthesia, particularly intrathecal anesthesia, has become the method of choice for elective cesarean deliveries.The most commonly used local anesthetic for intrathecal anesthesia is bupivacaine.Recent studies have focused on adjunctive agents to enhance the efficacy of local anesthetics.",[102],"Anesthesia",[104,105,106,107],"bupivacaine","dexmetomedine","spinal anesthesia","cessarian delivery","2026-03-09",{"date":110,"type":111},"2026-03-11","ACTUAL",{"date":113,"type":96},"2026-03-15",{"date":115,"type":96},"2026-10-15",{"name":5,"class":6},1]